Follow

Calmark participates in a Business Delegation visit to India

18 November 2022 - 08:00

Calmark Sweden AB (publ) will participate in a delegation trip to India on November 28 – December 2 organized by Swecare, in collaboration with the Ministry of Health and Social Affairs, the Embassy of Sweden New Delhi, the Consulate General in Mumbai and Business Sweden. In connection with the delegation, a promotion tour will be made in the country together with the company's distributor r2 Diagnostics.

Swecare is a foundation that was established in 1978 and whose mission is to contribute to increased exports of Swedish products, services and knowledge in the life science area. International delegation trips are part of Swecare's core business.

Head of this delegation is Mr. Niclas Jacobson, Deputy Director General at the Ministry of Health and Social Affairs. Participating from Calmark will be Magdalena Tharaldsen, Director International Business Development. High-level representatives from government agencies, healthcare and academia as well as life science companies will also join.

The delegation will start in Mumbai, with meetings with the State Ministry of Health, visits to premium healthcare facilities and to network with local stakeholders in a reception at the Consulate General. The trip then continues to Jodhpur, where Sweden has a close partner in All India Institute for Medical Sciences (AIIMS). Center of Excellence in Cancer Control will be presented, as well as the Innovation Center and the Swedish contributions. Future areas of collaboration will be explored. The last day will be spent in New Delhi with study visits to public and private healthcare providers, an informative meeting on Modicare and discussions on procurement and how Swedish solutions best can contribute to Indian healthcare.

"I am very much looking forward to this trip as India is an important market for us. It feels fantastic to have the opportunity to travel together with r2 Diagnostics and present how our Neo products can make a difference in India," says Magdalena Tharaldsen, Director International Business Development for Calmark. "During the trip, I will also pay a visit to the MAMTA Health Institute for Mother and Child. Connecting with important key people in neonatal care will give us many advantages now that our products soon are in the commercialization phase.”


Every care has been taken in the translation of this document. In the event of discrepancies, the Swedish original will supersede the English translation.

For more information about Calmark Sweden AB, please contact:

Camilla Arneving, Acting CEO
Telefon: +46 (0)10 204 01 50

E-post: [email protected]
www.calmark.se 

Calmark Sweden AB is a medical technology company that manufactures and markets a point-of-care (POC) analysis method with easier and faster diagnostics of medical conditions in newborns. The unique test platform consists of a portable instrument and test cassettes for various biomarkers. The first test, Neo-Bilirubin, is CE marked and measures the bilirubin level in whole blood for jaundice detection in newborns. In the Western world, the introduction of POC diagnostics is resulting in huge savings and shorter care chains. In less developed healthcare systems, the product offers a decision support which is currently lacking, since the access to hospital laboratories often is limited. Calmark aims to become the global leader in POC diagnostics for newborns and, in the long term, to offer all relevant tests for the first period of life. The B share is listed on the Spotlight Stock Market and is traded under the CALMA B ticker. Read more at www.calmark.se/eng/home.  

Provided by: Cision
Spotlight Stock Market (Sweden)
Calmark Sweden AB
Calmark is specialised in the development of diagnostic equipment for infants. The technology is based on a proprietary platform and is used for analysis during the first weeks after birth. The instrument is used as a biomarker to study blood count....
Learn more about company

Related news

We use cookies to make your experience using IPOhub better. By using our site you agree to our use of cookies. Learn More